Ser746
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
Home | Login
About PhosphoSiteUsing PhosphoSiteprivacy & cookiesCuration ProcessContact
logos LINCs Logo Mt Sinai Logo NIH Logo NCI Logo
Phosphorylation Site Page:
Ser746 - Kit (human)

Site Information
RRsVRIGsyIERDVT   SwissProt Entrez-Gene
Predicted information:  Scansite
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450036

In vivo Characterization
Methods used to characterize site in vivo: [32P] bio-synthetic labeling (3), mass spectrometry (1), mutation of modification site (3), phospho-antibody (2), phosphoamino acid analysis (3)
Disease tissue studied: HER2 positive breast cancer (1), luminal A breast cancer (1), luminal B breast cancer (1), breast cancer, triple negative (1)
Relevant cell line - cell type - tissue: breast (1), COS (fibroblast) (2), hematopoietic progenitor-bone marrow (2), PAE (endothelial) (3)

Controlled by
Kinases, in vitro: PKCA (human) (3)
Treatments: Ro31-8220 (2), SCF (2, 3)

Downstream Regulation
Effects of modification on Kit: enzymatic activity, inhibited (3), phosphorylation (3)


References

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Edling CE, et al. (2007) Haematopoietic progenitor cells utilise conventional PKC to suppress PKB/Akt activity in response to c-Kit stimulation. Br J Haematol 136, 260-8
17156394   Curated Info

3

Blume-Jensen P, Wernstedt C, Heldin CH, Rönnstrand L (1995) Identification of the major phosphorylation sites for protein kinase C in kit/stem cell factor receptor in vitro and in intact cells. J Biol Chem 270, 14192-200
7539802   Curated Info

Home  |  Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2017 Cell Signaling Technology, Inc.